MannKind

MannKind Corp. operates as a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

MannKind reports strong Q4 earnings, eyes revenue growth opportunities

MannKind's strong financial performance in Q4 2022, driven by revenue growth and improved margins, positions the company for future success.
While challenges exist in healthcare innovation and regulatory processes, MannKind's focus on internal innovation and revenue diversification presents growth opportunities.
Opportunities in collaborations, inhaled therapeutics, and data-driven healthcare outcomes offer avenues for MannKind's future expansion and profitability.
Maintaining financial stability, driving revenue growth, and exploring new product opportunities are key strategies for MannKind's long-term success.

MannKind reports strong Q1 performance, eyes revenue growth opportunities

MannKind's Q1 2023 earnings call highlighted strong performance in royalty revenue, endocrine business, and liquidity position. Challenges include maintaining growth amidst competition, while opportunities lie in revenue growth and strategic collaborations. Overall, MannKind's positive outlook is supported by its pipeline progress and focus on shareholder value.

MannKind achieves first operating income, eyes international expansion for growth

MannKind's Q2 performance reflects significant financial milestones, with revenue growth, operating income, and strong gross margins showcasing operational efficiency and progress towards profitability.
While facing challenges such as trial costs and regulatory requirements, the company's strategic strengths in product expansion, R&D investments, and international partnerships position it for long-term growth.
Opportunities in strong patient demand, international market expansion, orphan lung areas, and product growth present avenues for revenue diversification and sustained performance.
Overall, MannKind's focus on innovation, financial sustainability, and market expansion sets a positive trajectory for future growth and profitability.

MannKind achieves first profitable quarter with strong revenue growth

MannKind's Q3 marked a profitable quarter with significant revenue growth and operational improvements.
Strengths include revenue diversification, margin enhancements, and promising trial progress.
Challenges lie in stabilizing V-Go revenue, fluctuating earnings, and trial design adjustments.
Opportunities include upcoming milestones, market leverage, and Medicare changes for growth.

MannKind reports record 2023 revenues, eyes growth opportunities in 2024

MannKind had a strong financial performance in 2023, with a focus on debt repayment, clinical trials, and shareholder value in 2024. Innovation in powders and NTM asset, along with strategic positioning and sales force optimization, offer growth potential.

MannKind reports record revenue in Q2 2024 earnings call

MannKind's Q2 2024 performance reflects strong revenue growth and progress on key products.
While facing challenges in IP protection and manufacturing capacity, the company maintains a healthy cash position.
Opportunities lie in upcoming milestones and market expansion, with a focus on enhancing financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

WESTLAKE VILLAGE, Calif., Sept.  19, 2019  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced that data from a one-year study of Afrezza® (insulin human) Inhalation Powder was presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain.

MannKind Presents Positive Afrezza® Clinical Data from Type 1 Diabetes Study at 55th Annual Meeting of the EASD

MannKind presents at HC Wainwright Global Investment Conference.

MannKind: Investor Conference And Scripts - The Story Is Evolving

Clean Energy Fuels

CARBO Ceramics

Dean Foods

Nabors Industries

Signs are pointing to potential big gains for penny stocks in the coming days. These 5 dollars stocks are worth owning now.

5 Dollar Stocks to Buy Now

WESTLAKE VILLAGE, Calif., Aug.  30, 2019  (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 12:05 pm (ET) at the Lotte New York Palace Hotel in New York City. 

MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

Akcea Therapeutics

AMAG Pharmaceuticals

Eidos Therapeutics Inc

Ligand Pharmaceuticals

Moderna

Paratek Pharma

Viking Therapeutics

This has been a hard year for biotech. It seems that both Democrats and Republicans are wanting to target drug prices, and fears of universal health care in the years ahead would mean lower profitability for the sector as a whole.

8 Biotechs Being Choked by Short Sellers

MannKind Corporation (MNKD) CEO Michael Castagna on Q2 2019 Results - Earnings Call Transcript

Alexion Pharma

Amgen

Biogen

Celgene

Gilead Sciences

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Run for Cover From Major Biotechs

Shares rise after the company receives some praise from a pair of Wall Street analysts.

Why MannKind Is Up Big Today

MannKind Corporation (MNKD) CEO Michael Castagna on Q1 2019 Results - Earnings Call Transcript

Galmed Pharmaceuticals

Inovio Pharmaceuticals

La Jolla Pharmaceutical

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

News for MannKind Stock (MNKD)